95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1567793
This article is part of the Research Topic Community Series in Novel Reliable Approaches for Prediction and Clinical Decision-making in Cancer: Volume II View all 3 articles
Identification of disulfidptosis in esophageal squamous cell carcinoma based on single-cell and bulk RNA-seq data to predict prognosis and treatment response
Provisionally accepted
Xiaodan Zhang 1
Jianting Du 2*
Xiao Lin 2 Shuliang Zhang 2 Taidui Zeng 2 Maohui Chen 2 Guanglei Huang 2
Chun Chen 2
Bin Zheng 2*- 1 Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China
- 2 Fujian Medical University Union Hospital, Fuzhou, China
Purpose: Our study aims to identify the molecular subtypes of genes associated with disulfidptosis in esophageal squamous cell carcinoma(ESCC), develop a prognostic model, and identify potential therapeutic targets.Based on the GSE53625 expression profile data, we identified molecular subtypes with significant survival differences through consensus cluster analysis. Subsequently, univariate Cox, multivariate Cox, and LASSO-Cox regression analysis were used to establish risk stratification models. The transcriptome data of the TCGA-ESCC cohort and the GSE160269 single-cell sequencing dataset were integrated to verify the biological significance of the model, and further analyze the heterogeneity of the tumor immune microenvironment, explore the differences in the intercellular communication network, and screen potential targeted drugs, providing a theoretical basis for subsequent translational research.We identified two distinct patterns of disulfidptosis expression with significant differences in overall survival. Then, we constructed the prognostic signature of disulfidptosis, and results showed patients with high score had worse prognosis. Univariate and multivariate Cox analysis demonstrated that the constructed prognostic signature was an independent prognostic factor and was validated in an independent validation set. The two subgroups differed in the proportion of immune cell infiltration and related signaling pathways in ESCC. The exploration of immunotherapy data confirmed our prognostic signature also had certain predictive power for immunotherapy.Drug screening suggested AZD8186 and JQ1 as potential therapies for high-score patients.This study provides a new prognostic signature for ESCC, explores new therapeutic targets, and provides new theoretical support for personalized treatment.
Keywords: disulfidptosis, esophageal squamous cell carcinoma, prognostic analysis, Single-cell transcriptomic analysis, therapeutic strategy
Received: 28 Jan 2025; Accepted: 18 Mar 2025.
Copyright: © 2025 Zhang, Du, Lin, Zhang, Zeng, Chen, Huang, Chen and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jianting Du, Fujian Medical University Union Hospital, Fuzhou, China
Bin Zheng, Fujian Medical University Union Hospital, Fuzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.